Novel antiplatelet agent ticagrelor

刘美,刘梅林

2012-01-01

Abstract:Ticagrelor is the first reversible binding, direct-acting, oral adenosine diphosphate P2Y 12 receptor antagonist that has a more rapid onset and more pronounced platelet inhibition than clopidogrel. On Jul 20, 2011, the U. S. Food and Drug Administration approved ticagrelor to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndromes (ACS). Ticagrelor gave a greater reduction in the death rate from cardiovascular, myocardial infarction, or stroke than clopidogrel. No significant difference in the rate of major bleeding was found between the ticagrelor and clopidogrel groups. After any initial dose, use with aspirin 75~100 mg · d -1. This article reviews the pharmacological properties, clinical efficacy and adverse events of ticagrelor.